Eli Lilly and Company (LLY) is one of Wall Street's most broadly covered pharmaceutical names, and its analyst price targets span an unusually wide range. According to S&P Global data aggregating 31 analysts, the overall average price target is about $1,332, with individual figures running from roughly $930 to $1,600. The consensus rating is "Buy," with the majority of recent calls clustering in Strong Buy and Buy territory, alongside a small number of Hold, Sell, and Strong Sell ratings.
Because the overall mean of roughly $1,332 sits only about 4–5% above the last close near $1,273 — below a meaningful 10% threshold — the $1,430 central target used here is calculated differently. It reflects the arithmetic mean of verified individual targets that are above the current price. Recent examples include Morgan Stanley at $1,290, a $1,316 target, two firms at $1,400, a $1,413 target, and $1,500 targets from two firms including Citi, together with the $1,600 high. Averaging these above-price targets produces roughly $1,430.
Analysts differ mainly on how much credit to give Lilly's next pipeline wave and on how long premium GLP-1 pricing can persist. Bullish targets emphasize durable Mounjaro and Zepbound momentum, while more cautious views — including a September 2025 Berenberg downgrade to Hold — cite valuation and competitive intensity from rivals such as Novo Nordisk.
LLY closed near $1,273.46 on October 23, 2026, giving the stock a market capitalization of roughly $1.2 trillion. The 52-week range spans approximately $809.63 to $1,321.21, with the stock trading near the top of that range after a gain of more than 50% over the trailing year. Reaching $1,430 would require an advance of about 12%, a modest move relative to the stock's recent volatility.
The path toward such a level would likely depend on continued execution in the cardiometabolic portfolio. Lilly's GLP-1 drugs Mounjaro (type 2 diabetes) and Zepbound (obesity) have driven strong revenue growth; in the third quarter of 2025, revenue rose to roughly $17.6 billion, up sharply from about $11.4 billion a year earlier. Trailing-twelve-month revenue now approaches $80 billion, with a net margin above 30%. Valuation remains elevated at a trailing P/E (price-to-earnings ratio) near 43 times and a forward P/E in the low-30s, meaning further upside would likely need to be earnings-driven rather than multiple-driven.
The stock set a 52-week high of $1,321.21 on October 22, 2026, making the $1,300–$1,320 zone a key resistance level that must be cleared for any push toward $1,430. A sustained breakout above that zone would put the central target within reach. On the downside, the $1,250–$1,260 area has acted as near-term support, with the more durable 52-week low near $810 marking the lower bound of the long-term trend. The broader uptrend remains intact, but the stock's proximity to all-time highs leaves little room for a momentum pause without stalling the advance.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms apply different methodologies and time frames. The most important near-term event is Lilly's next earnings report, expected on or around October 29, 2026, before the market open. Investors should monitor GLP-1 prescription trends and pricing, updates on manufacturing capacity, any guidance changes, analyst target revisions following results, and broader policy or regulatory developments affecting drug pricing. Macroeconomic factors, including interest-rate decisions, can also influence the valuation investors are willing to pay for high-multiple growth stocks.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. Rather than replacing fundamental research, the tool is designed to help traders discover opportunities, monitor existing positions, and spot changing trends more efficiently across the market. For investors tracking a large-cap name like LLY, such signals can complement a broader research process by highlighting short-term momentum shifts alongside the longer-term analyst price target debate.
Whether Eli Lilly and Company (LLY) can reach $1,430 depends less on headline sentiment than on continued execution in its GLP-1 franchise and the market's willingness to sustain a premium multiple. The target — the average of verified analyst targets above the current price — requires a modest roughly 12% advance from the last close near $1,273. The overall analyst mean of about $1,332 and the wide $930–$1,600 range highlight genuine disagreement about how much of Lilly's growth is already priced in. Strong demand for Mounjaro and Zepbound, upward estimate revisions, and a robust pipeline support the bull case, while valuation, competition, and pricing regulation are the principal obstacles. With earnings due in late October, near-term guidance and prescription data will be the most important signals to watch. No price target is a guarantee, and investors should weigh both the upside and the risks before drawing conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, LLY has been loosely correlated with JNJ. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then JNJ could also see price increases.